$0.84
-0.01 (-1.14%)
Open$0.84
Previous Close$0.85
Day High$0.86
Day Low$0.81
52W High$5.33
52W Low$0.94
Volume—
Avg Volume1.47M
Market Cap45.38M
P/E Ratio—
EPS$-1.02
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,192.4% upside
Current
$0.84
$0.84
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 99.50M | 69.69M | 27.35M |
| Net Income | -30,918,872 | -19,488,048 | 6.20M |
| Profit Margin | -31.1% | -29.5% | 22.7% |
| EBITDA | -6,940,501 | -4,617,603 | 9.44M |
| Free Cash Flow | — | — | 4.10M |
| Rev Growth | +42.8% | +42.8% | -0.5% |
| Debt/Equity | 4.00 | 4.00 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $213.76 | +2.08% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $330.33 | -0.13% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $130.28 | -0.17% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $429.32 | -1.15% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $641.69 | +1.81% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.86 | -0.15% | 66.6 | 38.43B |